Home/Filings/4/0001209191-19-026036
4//SEC Filing

Benedict Larry 4

Accession 0001209191-19-026036

CIK 0001423824other

Filed

Apr 24, 8:00 PM ET

Accepted

Apr 25, 6:53 PM ET

Size

7.9 KB

Accession

0001209191-19-026036

Insider Transaction Report

Form 4
Period: 2019-04-23
Benedict Larry
Sr. VP Finance
Transactions
  • Award

    Common Stock

    2019-04-23+7,05541,462 total
  • Sale

    Common Stock

    2019-04-25$13.65/sh1,734$23,66239,728 total
Footnotes (3)
  • [F1]On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 21,165 shares of Issuer's Common Stock (the "RSU"). Up to 7,055 shares subject to the RSU vest upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the "FDA") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the "FDA Filing Milestone") and the remaining shares subject to the RSU vest upon certain other performance criteria. On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 7,055 shares subject to the RSU.
  • [F2]Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSU. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.6461 to $13.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.

Issuer

ALDER BIOPHARMACEUTICALS INC

CIK 0001423824

Entity typeother

Related Parties

1
  • filerCIK 0001604805

Filing Metadata

Form type
4
Filed
Apr 24, 8:00 PM ET
Accepted
Apr 25, 6:53 PM ET
Size
7.9 KB